15 completed, 3 terminated, 1 recruiting. 19 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 15, Terminated 3, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow dacomitinib: new trials by email Literature Review of dacomitinib trials Research Report on dacomitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations Dacomitinib+Anlotinib, Dacomitinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 140 | 2022-10-13 | 2023-04-19 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Evaluate Severe Hepatic Impairment on Dacomitinib PK Dacomitinib - Severe Hepatic Impairment | Phase 1 | Completed | Pfizer | 16 | 2019-04-05 | 2020-11-06 |
| Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Dacomitinib, Osimertinib - Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2019-01-17 | 2025-12-23 |
| Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers Dacomitinib - Healthy | Phase 1 | Completed | Pfizer | 14 | 2014-07-01 | 2014-10-03 |
| Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC Dacomitinib, PD-0325901, Docetaxel - Colorectal Cancer | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 35 | 2014-04-02 | 2025-07-08 |
| A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) PF-05212384 (gedatolisib), Docetaxel, Cisplatin - Neoplasm | Phase 1 | Completed | Pfizer | 110 | 2013-09-10 | 2022-09-13 |
| Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Dacomitinib, Pemetrexed - Non Small Cell Lung Cancer | Phase 1 | Terminated | Central European Cooperative Oncology Group | 5 | 2013-07-30 | 2019-12-30 |
| A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers dacomitinib oral, dacomitinib intravenous - Healthy Volunteers | Phase 1 | Completed | Pfizer | 14 | 2013-04-01 | 2015-10-08 |
| Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck dacomitinib, Radiotherapy, Cisplatin - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | University Health Network, Toronto | 12 | 2013-01-01 | 2016-06-13 |
| A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment dacomitinib - Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction | Phase 1 | Completed | Pfizer | 25 | 2012-04-01 | 2013-12-18 |
| A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer PF-02341066, PF-00299804 - Non Small Cell Lung Cancer | Phase 1 | Completed | Pfizer | 70 | 2010-08-01 | 2015-10-28 |
| Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment PF-00299804 - Oral Cavity Cancer | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 13 | 2010-05-01 | 2015-07-10 |
| A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 PF-00299804 - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | Pfizer | 22 | 2010-02-01 | 2012-06-22 |
| A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers reference [dextromethorphan], test [PF-00299804 + dextromethorphan] - Healthy Volunteers | Phase 1 | Completed | Pfizer | 14 | 2009-11-01 | 2010-01-07 |
| A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks PF-00299804 - Carcinoma, Non-Small Cell, Neoplasm Metastasis | Phase 1 | Completed | Pfizer | 74 | 2008-12-15 | 2024-04-22 |
| A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors PF-00299804 - Neoplasms | Phase 1 | Completed | Pfizer | 13 | 2008-11-01 | 2011-06-27 |
| A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients PF-00299804 - Advanced Malignant Solid Tumors | Phase 1 | Completed | Pfizer | 16 | 2008-09-01 | 2017-08-02 |
| Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors PF-00299804 - Neoplasms | Phase 1 | Completed | Pfizer | 121 | 2005-10-11 | 2018-12-21 |
Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (3) · Neoplasms (3) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1)
Pfizer (12) · University Health Network, Toronto (2) · Central European Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · OHSU Knight Cancer Institute (1) · Shanghai Chest Hospital (1) · The Netherlands Cancer Institute (1)
United States (10) · Canada (3) · China (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · France (1) · Italy (1) · Japan (1)
Christoph C Zielinski, Univ. Prof. (1) · Helena Yu, MD (1) · Lara Davis, MD (1) · Lillian Siu, M.D. (1) · Lillian Siu, MD, FRCPC (1)
PMID 35195881, PMID 21220471, PMID 22249430, PMID 25937431, PMID 26048096, PMID 32147669, PMID 34140482, PMID 36335217, PMID 39863139
2005 (1)